SRPT

Sarepta Therapeutics Inc

SRPT, USA

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

https://www.sarepta.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SRPT
stock
SRPT

Sarepta Therapeutics stock falls after debt exchange announcement Investing.com India

Read more →
SRPT
stock
SRPT

Why Is SRPT Stock Falling Today? Stocktwits

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$19.9091

Analyst Picks

Strong Buy

14

Buy

8

Hold

4

Sell

0

Strong Sell

0

Sentiment:

Neutral

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Low

1.65

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-13.63 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-5.15 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-10.73 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.65

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 76.73% of the total shares of Sarepta Therapeutics Inc

1.

BlackRock Inc

(11.5745%)

since

2025/06/30

2.

Vanguard Group Inc

(8.7513%)

since

2025/06/30

3.

iShares Core S&P Small-Cap ETF

(5.5697%)

since

2025/08/31

4.

State Street Corp

(4.4855%)

since

2025/06/30

5.

D. E. Shaw & Co LP

(4.2787%)

since

2025/06/30

6.

Vanguard Total Stock Mkt Idx Inv

(2.8311%)

since

2025/07/31

7.

Wellington Management Company LLP

(2.4175%)

since

2025/06/30

8.

Vanguard Small Cap Index

(2.1699%)

since

2025/07/31

9.

Two Sigma Investments LLC

(2.0652%)

since

2025/06/30

10.

Vanguard Health Care Inv

(2.0181%)

since

2025/06/30

11.

Two Sigma Advisers, LLC

(1.8971%)

since

2025/06/30

12.

Geode Capital Management, LLC

(1.7923%)

since

2025/06/30

13.

First Trust NYSE Arca Biotech ETF

(1.7905%)

since

2025/08/28

14.

SPDR® S&P Biotech ETF

(1.7274%)

since

2025/08/31

15.

Erste Asset Management GmbH

(1.549%)

since

2025/06/30

16.

Qube Research & Technologies

(1.5271%)

since

2025/06/30

17.

Morgan Stanley - Brokerage Accounts

(1.4206%)

since

2025/06/30

18.

VOLORIDGE INVESTMENT MANAGEMENT, LLC

(1.4084%)

since

2025/06/30

19.

Federated Hermes Inc

(1.2498%)

since

2025/06/30

20.

Vanguard Small Cap Growth Index Inv

(1.2241%)

since

2025/07/31

21.

Aberdeen Group PLC

(1.187%)

since

2025/06/30

22.

BNP Paribas Arbitrage, SA

(1.1787%)

since

2025/06/30

23.

Millennium Management LLC

(1.0148%)

since

2025/06/30

24.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0082%)

since

2025/07/31

25.

Casdin Capital, LLC

(0.9459%)

since

2025/06/30

26.

Bank of America Corp

(0.8759%)

since

2025/06/30

27.

NORGES BANK

(0.8726%)

since

2025/06/30

28.

Y-Intercept (Hong Kong) Ltd

(0.8313%)

since

2025/06/30

29.

iShares S&P Small-Cap 600 Growth ETF

(0.8078%)

since

2025/08/31

30.

SPDR® S&P MIDCAP 400 ETF Trust

(0.7192%)

since

2025/07/31

31.

Federated Hermes MDT Mid Cap Growth A

(0.7025%)

since

2025/06/30

32.

Federated Hermes MDT MCG Institutional

(0.7025%)

since

2025/06/30

33.

abrdn Healthcare Investors

(0.5705%)

since

2025/08/31

34.

T. Rowe Price Small-Cap Value

(0.5488%)

since

2025/07/31

35.

iShares Biotechnology ETF

(0.534%)

since

2025/08/31

36.

abrdn Healthcare Opportunities

(0.5283%)

since

2025/07/31

37.

Fidelity Extended Market Index

(0.5086%)

since

2025/07/31

38.

iShares Russell Mid-Cap Growth ETF

(0.49%)

since

2025/08/31

39.

American Funds IS® Growth 1

(0.4761%)

since

2025/06/30

40.

Capital Group Growth Composite

(0.4761%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-1.05

Latest Release

Date

2025-09-30

EPS Actual

-0.13

EPS Estimate

-0.6985

EPS Difference

0.5685

Surprise Percent

81.3887%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(1.5)
Momentum
Moderate Momentum(5.5)
Net Net
Not Undervalued (Net-Net)(1.5)
Quality
Low Quality Business(1.5)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.